Two CDK 4/6 inhibitors prolong survival in HR+/HER2- breast cancer in pre- and post-menopausal women
CDK 4/6 inhibitors in combination with endocrine therapy are confirmed to be beneficial in patients with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer across the board, and no matter which agent is used, as results from…
Read More